SEC Filing Analysis: RESMED INC (RMD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chairman and CEO, Michael J. Farrell, conducted a routine, pre-planned sale of stock valued at approximately $2 million to cover the cost of exercising expiring stock options.
• Market Impact: The transaction is considered immaterial and is unlikely to have any impact on the stock price due to its small size and pre-scheduled nature under a Rule 10b5-1 plan.

Company Information

Field	Value
Company	RESMED INC
Ticker Symbol	RMD
CIK	0000943819
Industry	Surgical & Medical Instruments & Apparatus

Insider Information

Field	Value
Name	Farrell Michael J.
CIK	0001485164
Title/Position	Chairman and CEO
Relationship	Director, Officer

Transaction Details

This filing reports an option exercise immediately followed by a sale to cover. The most relevant market event is the sale:

Field	Value
Form Type	4
Transaction Date	2025-11-07
Transaction Code	S (Sale)
Security Type	ResMed Common Stock
Shares Involved	8,011
Price Per Share	$249.7532 (Weighted Average)
Total Value	$2,000,748.35
Shares Owned After	467,866 (Directly)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$2,000,748
% of Market Cap	0.005%
Shares Transacted	8,011
% of Shares Outstanding	0.005%
Post-Transaction Ownership	469,956 shares (0.321% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $2 million sale is negligible for a company with a market capitalization of $36.71 billion.
• Ownership Concentration: The sale represents a very small fraction (approx. 1.7%) of the CEO's direct holdings prior to the transaction. He maintains a significant stake in the company valued at over $117 million post-sale.
• Dilution Impact: The transaction involved exercising existing options, which were already accounted for in diluted share counts. The net effect is neutral as the shares were immediately sold.
• Transaction Significance: The transaction's value is less than 0.01% of the market cap and shares outstanding, placing it firmly in the 'Low' significance category. It is a routine executive compensation activity.

Additional Context

Transaction Notes

• Special Circumstances: The transactions were executed under a Rule 10b5-1 trading plan adopted on October 31, 2024. This indicates the sale was pre-scheduled and not based on any immediate material non-public information.